Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04344756

Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort — CORIMMUNO-COAG  

COVID19 Pneumonia Clinical Trial

Official title:
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial

Clinical Trial Summary

COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent Covid-19 or infection with SARS-CoV-2 or therapeutic agent to treat COVID-19.

This protocol CORIMUNO19-COAG will evaluate the efficacy and safety of active anticoagulation using heparin: Tinzaparin (INNOHEP®) or unfractionated heparin (Calciparine®, Héparine Sodique Choay®) in COVID-19 patients hospitalized in conventional or intensive care units.

It will use a phase 2 randomized open-label multicentre clinical trial, where patients will be randomly allocated to anticoagulation versus Standard of Care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04344756
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Tristan Mirault
Phone 1 56 09 50 41
Email tristan.mirault@aphp.fr
Status Not yet recruiting
Phase Phase 2
Start date April 20, 2020
Completion date September 30, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT04565379 - Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients Phase 2
Recruiting NCT04527224 - Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia Phase 1/Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Recruiting NCT04642040 - Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia N/A
Recruiting NCT04487951 - N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia
Active, not recruiting NCT04881214 - COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program N/A
Recruiting NCT04377750 - The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Phase 4
Recruiting NCT04569227 - Prevention of COVID-19 Infection to Severe Pneumonia or ARDS Phase 2
Completed NCT04535063 - Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04344782 - Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Phase 2